
1. eur urol. 2017 jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. epub 2017
apr 10.

an oncofetal glycosaminoglycan modification provides therapeutic access to
cisplatin-resistant bladder cancer.

seiler r(1), oo hz(2), tortora d(2), clausen tm(3), wang ck(4), kumar g(4),
pereira ma(5), ørum-madsen ms(2), agerbæk mø(3), gustavsson t(5), nordmaj ma(5), 
rich jr(6), lallous n(2), fazli l(2), lee ss(7), douglas j(8), todenhöfer t(2),
esfandnia s(2), battsogt d(7), babcook js(6), al-nakouzi n(2), crabb sj(9),
moskalev i(7), kiss b(10), davicioni e(11), thalmann gn(10), rennie ps(2), black 
pc(2), salanti a(5), daugaard m(12).

author information: 
(1)department urologic sciences, university british columbia, vancouver,
bc, canada; vancouver prostate centre, vancouver, bc, canada; department of
urology, university bern, bern, switzerland.
(2)department urologic sciences, university british columbia, vancouver,
bc, canada; vancouver prostate centre, vancouver, bc, canada.
(3)department urologic sciences, university british columbia, vancouver,
bc, canada; vancouver prostate centre, vancouver, bc, canada; department of
immunology microbiology, centre medical parasitology, university of
copenhagen, copenhagen, denmark; department infectious diseases, copenhagen
university hospital, copenhagen, denmark.
(4)department urologic sciences, university british columbia, vancouver,
bc, canada; vancouver prostate centre, vancouver, bc, canada; department of
pathology laboratory medicine, university british columbia, vancouver, bc,
canada.
(5)department immunology microbiology, centre medical parasitology,
university copenhagen, copenhagen, denmark; department infectious diseases,
copenhagen university hospital, copenhagen, denmark.
(6)zymeworks inc., vancouver, bc, canada.
(7)vancouver prostate centre, vancouver, bc, canada.
(8)department urology, university hospital southampton, hampshire, uk.
(9)department medical oncology, university hospital southampton, hampshire,
uk.
(10)department urology, university bern, bern, switzerland.
(11)genomedx biosciences, inc., vancouver, bc, canada.
(12)department urologic sciences, university british columbia, vancouver,
bc, canada; vancouver prostate centre, vancouver, bc, canada; zymeworks inc.,
vancouver, bc, canada. electronic address: mads.daugaard@ubc.ca.

comment in
    nat rev urol. 2017 jun;14(6):326.

background: although cisplatin-based neoadjuvant chemotherapy (nac) improves
survival unselected patients muscle-invasive bladder cancer (mibc), 
a minority responds therapy chemoresistance remains major challenge in
this disease setting.
objective: investigate clinical significance oncofetal chondroitin
sulfate (ofcs) glycosaminoglycan chains cisplatin-resistant mibc to
evaluate targets second-line therapy.
design, setting, participants: ofcs-binding recombinant var2csa protein
derived malaria parasite plasmodium falciparum (rvar2) used in
situ, vitro, vivo ofcs-targeting reagent cisplatin-resistant mibc.
the ofcs expression landscape analyzed two independent cohorts matched 
pre- post-nac-treated mibc patients.
intervention: rvar2 protein armed cytotoxic hemiasterlin compounds (rvar2
drug conjugate [vdc] 886) evaluated novel therapeutic strategy a
xenograft model cisplatin-resistant mibc.
outcome measurements statistical analysis: antineoplastic effects of
targeting ofcs.
results limitations: situ, ofcs significantly overexpressed in
residual tumors nac two independent patient cohorts (p<0.02). global
gene-expression profiling biochemical analysis primary tumors cell
lines revealed syndican-1 chondroitin sulfate proteoglycan 4 ofcs-modified
proteoglycans mibc. vitro, ofcs expressed mibc cell lines
tested, vdc886 eliminated cells low-nanomolar ic50 concentration
range. vivo, vdc886 effectively retarded growth chemoresistant orthotopic
bladder cancer xenografts prolonged survival (p=0.005). use cisplatin 
only generation chemoresistant xenografts limitations our
animal model design.
conclusions: targeting ofcs provides promising second-line treatment strategy
in cisplatin-resistant mibc.
patient summary: cisplatin-resistant bladder cancer overexpresses particular
sugar chains compared chemotherapy-naïve bladder cancer. using recombinant
protein malaria parasite plasmodium falciparum, target these
sugar chains, results showed significant antitumor effect in
cisplatin-resistant bladder cancer. novel treatment paradigm provides
therapeutic access bladder cancers responding cisplatin.

copyright © 2017 european association urology. rights reserved.

doi: 10.1016/j.eururo.2017.03.021 
pmid: 28408175  [indexed medline]

